Background Colombia began official surveillance for Zika virus disease (ZVD) in August 2015. In October 2015, an outbreak of ZVD was declared after laboratory-confirmed disease was identified in nine patients. Methods Using the national population-based surveillance system, we assessed patients with clinical symptoms of ZVD from August 9, 2015, to April 2, 2016. Laboratory test results and pregnancy outcomes were evaluated for a subgroup of pregnant women. Concurrently, we investigated reports of microcephaly for evidence of congenital ZVD. Results By April 2, 2016, there were 65,726 cases of ZVD reported in Colombia, of which 2485 (4%) were confirmed by means of reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay. The overall reported incidence of ZVD among female patients was twice that in male patients. A total of 11,944 pregnant women with ZVD were reported in Colombia, with 1484 (12%) of these cases confirmed on RT-PCR assay. In a subgroup of 1850 pregnant women, more than 90% of women who were reportedly infected during the third trimester had given birth, and no infants with apparent abnormalities, including microcephaly, have been identified. A majority of the women who contracted ZVD in the first or second trimester were still pregnant at the time of this report. Among the cases of microcephaly investigated from January 2016 through April 2016, four patients had laboratory evidence of congenital ZVD; all were born to asymptomatic mothers who were not included in the ZVD surveillance system. Conclusions Preliminary surveillance data in Colombia suggest that maternal infection with the Zika virus during the third trimester of pregnancy is not linked to structural abnormalities in the fetus. However, the monitoring of the effect of ZVD on pregnant women in Colombia is ongoing. (Funded by Colombian Instituto Nacional de Salud and the Centers for Disease Control and Prevention.).
<p>Background. In Colombia, maternal near miss morbidity is<br />monitored in the health surveillance system. The National<br />Health Institute included a special report on cases that met<br />three or more World Health Organization criteria according to<br />the World Health Organization criteria.</p><p><br />Objective. To estimate the relationship between variables<br />related to opportune access to health care services in Colombia during 2013 depending on inclusion criteria –three or more– for maternal near miss morbidity.</p><p><br />Materials and methods. A cross-sectional analysis of the<br />national registry of obligatory notification on maternal near<br />miss morbidity was performed. Cases with three or more criteria were compared with those with one or two according to some variables related to the timely access of health care services.</p><p><br />Results. A total of 8 434 maternal near miss morbidity cases<br />were reported, women were aged between 12 and 51 years old<br />(M=26.4, SD=7.5). 961 (11.4%) lived in remote rural areas; 4<br />537 (53.8%) were uninsured under the health system, or they<br />were affiliated to either the subsidized or special health care<br />regime; 845 (10.0%) belonged to an ethnic minority; 3 696<br />(44.4%) were referred to a more complex service; 4 097 (49.2%) were admitted to the intensive care unit; and 3 975 (47.1%) met three or more of the inclusion criteria for maternal near miss morbidity. They were combined to meet three or more of the case inclusion criteria: intensive care unit admission (OR=5.58;IC95% 5.06-6.15); being uninsured or affiliated to the subsidized or special regime (OR=1.57; IC95% 1.42-1.74); and referral to a more complex service (OR=1.18; IC95% 1.07-1.31).</p><p><br />Conclusions. In Colombia, the timely access of health care<br />services is related to maternal near miss morbidity with three<br />or more inclusion criteria.</p>
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.